Explore 3 Stock Ideas & Industry Insights Download Free Report

HLK Biotech Holding Group Inc

Healthcare US AMHD

0.0002USD
0.00(0%)

Last update at 2026-06-18T13:30:00Z

Day Range

0.00020.0002
LowHigh

52 Week Range

0.00020.0002
LowHigh

Fundamentals

  • Previous Close 0.0002
  • Market Cap0.00093M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.70117M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.18000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2016-12-31 2015-12-31 2014-12-31 1998-12-31 1997-12-31
Type yearly yearly yearly yearly yearly
Date 2016-12-31 2015-12-31 2014-12-31 1998-12-31 1997-12-31
Income before tax -0.00377M 0.00000M -0.01909M -1.03834M -0.96156M
Minority interest - - - - -
Net income -0.00377M 0.00000M -0.01909M -1.03834M -0.96156M
Selling general administrative 0.00668M 0.01M 0.03M 0.52M 0.96M
Selling and marketing expenses - - - - -
Gross profit 0.00833M 0.01M 0.02M -0.18000M 0.00000M
Reconciled depreciation - - - - -
Ebit -0.00091M 0.00532M -0.01136M -0.70739M -0.96156M
Ebitda - - - - -
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -0.00091M -0.00312M -0.01136M -0.70739M -0.96156M
Other operating expenses 0.00256M 0.00256M 0.00256M - -
Interest expense 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total revenue 0.00833M 0.01M 0.02M 0.00000M 0.00000M
Total operating expenses 0.00000M 0.00000M 0.00000M 0.71M 0.96M
Cost of revenue 0.00000M 0.00000M 0.00000M 0.18M 0.00000M
Total other income expense net - 0.00844M 0.00844M -0.33095M 0.00000M
Discontinued operations - - - - -
Net income from continuing ops -0.00377M 0.00000M -0.01909M -1.03834M -0.96156M
Net income applicable to common shares -0.00377M 0.00000M -0.01909M -1.03834M -0.96156M
Preferred stock and other adjustments - - - - -
Breakdown 2016-12-31 2015-12-31 2014-12-31 1998-12-31 1997-12-31
Type yearly yearly yearly yearly yearly
Date 2016-12-31 2015-12-31 2014-12-31 1998-12-31 1997-12-31
Total assets 0.12M 0.12M 0.12M 0.85M 0.06M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - 0.03M -
Total liab 0.06M 0.06M 0.07M 1.48M 0.04M
Total stockholder equity 0.05M 0.06M 0.06M -0.62347M 0.02M
Deferred long term liab - - - - -
Other current liab - - - - -
Common stock 0.46M 0.46M 0.46M 0.02M 0.01M
Capital stock - - - - -
Retained earnings -4.87472M -4.87095M -4.87095M -1.11847M -0.08013M
Other liab 0.05M 0.02M - - -
Good will - - - 0.60M -
Other assets - - - 0.00064M -
Cash 0.00240M 0.00001M 0.00008M 0.06M 0.00087M
Cash and equivalents - - - - -
Total current liabilities 0.02M 0.03M 0.02M 1.08M 0.04M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt 0.02M 0.03M 0.02M 0.10M 0.03M
Short long term debt 0.02M 0.03M 0.02M 0.10M 0.03M
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment 0.11M 0.11M 0.11M 0.09M -
Total current assets 0.00240M 0.00001M 0.00008M 0.17M 0.06M
Long term investments 0.00860M 0.00860M 0.01M 0.00100M -
Net tangible assets 0.05M 0.06M 0.06M -1.22050M 0.02M
Short term investments - - - - -
Net receivables - - - 0.00100M -
Long term debt - 0.02M 0.04M 0.40M -
Inventory - - - - -
Accounts payable - - - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total - - - - -
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2016-12-31 2015-12-31 2014-12-31 1998-12-31 1997-12-31
Type yearly yearly yearly yearly yearly
Date 2016-12-31 2015-12-31 2014-12-31 1998-12-31 1997-12-31
Investments - - - -0.11100M -0.11100M
Change to liabilities - - - 0.26M 0.25M
Total cashflows from investing activities - - - -0.31174M -0.31174M
Net borrowings 0.00360M -0.00264M 0.02M 0.66M 0.24M
Total cash from financing activities 0.00360M -0.00264M 0.01M 0.82M 1.38M
Change to operating activities - - - 0.00314M -0.72000M
Net income -0.00377M 0.00000M -0.01909M -1.03834M -0.96156M
Change in cash 0.00240M -0.00008M -0.00268M 0.06M 0.01M
Begin period cash flow - - - - -
End period cash flow - - - - -
Total cash from operating activities -0.00120M 0.00257M -0.01653M -0.44175M -1.36956M
Issuance of capital stock - - - - -
Depreciation 0.00256M 0.00256M 0.00256M 0.00623M 0.00623M
Other cashflows from investing activities - - - -0.20900M -0.20900M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - 0.20M 1.20M
Other cashflows from financing activities - - - -0.04400M -0.06000M
Change to netincome - - - 0.32M 0.06M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - - - - -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow - - - - -

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
AMHD
HLK Biotech Holding Group Inc
- -% 0.0002 - - - -
ZTS
Zoetis Inc
-2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR
-0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
- -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG
- -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

Profile

HLK Biotech Holding Group, Inc., through its subsidiaries, produces and sells biodiesel. It also acquires real estate properties. The company was formerly known as Amelot Holdings, Inc. and changed its name to HLK Biotech Holding Group, Inc. in February 2018. HLK Biotech Holding Group, Inc. is headquartered in Norfolk, Virginia.

HLK Biotech Holding Group Inc

2612 Granby Street, Norfolk, VA, United States, 23517

Key Executives

Name Title Year Born
Dr. Anna Petinova Interim VP of Admin., Interim VP of Fin., Treasurer and Director 1964
Mr. Hank Midden VP - Operations 1942
Mr. John Gernannt Head of Investor & PR Issues NA
Mr. Peter R. N. Maharaj VP - Marketing and Pres - Southern Hardwoods 1966
Mr. Thomas Cripe Sr. VP of Bus. & Technology Devel. NA
Mr. Tyler Macallister Controller NA
Dr. Anna Petinova Interim Vice President of Administration, Interim Vice President of Finance, Treasurer and Director 1964
Mr. Hank Midden Vice President - Operations 1942
Mr. John Gernannt Head of Investor & Public Relations Issues NA
Mr. Peter R. N. Maharaj Vice President - Marketing and President - Southern Hardwoods 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.